vs

Side-by-side financial comparison of CASTLE BIOSCIENCES INC (CSTL) and NewtekOne, Inc. (NEWT). Click either name above to swap in a different company.

CASTLE BIOSCIENCES INC is the larger business by last-quarter revenue ($83.7M vs $73.3M, roughly 1.1× NewtekOne, Inc.). NewtekOne, Inc. runs the higher net margin — 111.8% vs -17.4%, a 129.1% gap on every dollar of revenue. On growth, NewtekOne, Inc. posted the faster year-over-year revenue change (-2.7% vs -4.9%). Over the past eight quarters, NewtekOne, Inc.'s revenue compounded faster (12.2% CAGR vs -1.9%).

Castle Biosciences Inc. is a commercial-stage diagnostic firm that develops and markets proprietary, clinically actionable tests for dermatological conditions such as melanoma and other skin cancers, plus rare diseases. It operates mainly in the U.S. healthcare market, focusing on segments with high unmet need for more accurate diagnostics to guide treatment choices.

NewTek, Inc., is a hardware and software company, based in San Antonio, Texas, that produced live and post-production video tools and visual imaging software for personal computers. The company was founded in 1985 in Topeka, Kansas, United States, by Tim Jenison and Paul Montgomery. On April 1, 2019, it was announced that NewTek would be acquired by Vizrt.

CSTL vs NEWT — Head-to-Head

Bigger by revenue
CSTL
CSTL
1.1× larger
CSTL
$83.7M
$73.3M
NEWT
Growing faster (revenue YoY)
NEWT
NEWT
+2.2% gap
NEWT
-2.7%
-4.9%
CSTL
Higher net margin
NEWT
NEWT
129.1% more per $
NEWT
111.8%
-17.4%
CSTL
Faster 2-yr revenue CAGR
NEWT
NEWT
Annualised
NEWT
12.2%
-1.9%
CSTL

Income Statement — Q1 FY2026 vs Q4 FY2025

Metric
CSTL
CSTL
NEWT
NEWT
Revenue
$83.7M
$73.3M
Net Profit
$-14.5M
$19.5M
Gross Margin
Operating Margin
Net Margin
-17.4%
111.8%
Revenue YoY
-4.9%
-2.7%
Net Profit YoY
43.8%
6.6%
EPS (diluted)
$-0.49
$0.64

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CSTL
CSTL
NEWT
NEWT
Q1 26
$83.7M
Q4 25
$87.0M
$73.3M
Q3 25
$83.0M
$74.9M
Q2 25
$86.2M
$70.2M
Q1 25
$88.0M
$66.3M
Q4 24
$86.3M
$75.4M
Q3 24
$85.8M
$62.8M
Q2 24
$87.0M
$61.1M
Net Profit
CSTL
CSTL
NEWT
NEWT
Q1 26
$-14.5M
Q4 25
$19.5M
Q3 25
$-501.0K
$17.9M
Q2 25
$4.5M
$13.7M
Q1 25
$-25.8M
$9.4M
Q4 24
$18.3M
Q3 24
$2.3M
$11.9M
Q2 24
$8.9M
$10.9M
Gross Margin
CSTL
CSTL
NEWT
NEWT
Q1 26
Q4 25
79.0%
Q3 25
77.5%
Q2 25
79.5%
Q1 25
81.4%
Q4 24
81.3%
Q3 24
81.8%
Q2 24
83.3%
Operating Margin
CSTL
CSTL
NEWT
NEWT
Q1 26
Q4 25
-4.4%
Q3 25
-8.2%
Q2 25
-4.9%
Q1 25
-31.7%
Q4 24
4.7%
Q3 24
5.9%
Q2 24
5.8%
Net Margin
CSTL
CSTL
NEWT
NEWT
Q1 26
-17.4%
Q4 25
111.8%
Q3 25
-0.6%
23.9%
Q2 25
5.2%
19.5%
Q1 25
-29.4%
14.1%
Q4 24
24.3%
Q3 24
2.6%
19.0%
Q2 24
10.3%
17.9%
EPS (diluted)
CSTL
CSTL
NEWT
NEWT
Q1 26
$-0.49
Q4 25
$-0.06
$0.64
Q3 25
$-0.02
$0.67
Q2 25
$0.15
$0.52
Q1 25
$-0.90
$0.35
Q4 24
$0.32
$0.70
Q3 24
$0.08
$0.45
Q2 24
$0.31
$0.43

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CSTL
CSTL
NEWT
NEWT
Cash + ST InvestmentsLiquidity on hand
$63.8M
Total DebtLower is stronger
$10.1M
$819.9M
Stockholders' EquityBook value
$461.4M
$397.6M
Total Assets
$547.8M
$2.7B
Debt / EquityLower = less leverage
0.02×
2.06×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CSTL
CSTL
NEWT
NEWT
Q1 26
$63.8M
Q4 25
$299.5M
Q3 25
$287.5M
Q2 25
$275.9M
Q1 25
$275.2M
Q4 24
$293.1M
Q3 24
$95.0M
Q2 24
$85.6M
Total Debt
CSTL
CSTL
NEWT
NEWT
Q1 26
$10.1M
Q4 25
$10.1M
$819.9M
Q3 25
$10.0M
$748.5M
Q2 25
$10.0M
$657.3M
Q1 25
$10.0M
$774.0M
Q4 24
$10.0M
$708.0M
Q3 24
$10.0M
$655.8M
Q2 24
$10.0M
$652.0M
Stockholders' Equity
CSTL
CSTL
NEWT
NEWT
Q1 26
$461.4M
Q4 25
$470.9M
$397.6M
Q3 25
$467.0M
$386.7M
Q2 25
$455.4M
$312.2M
Q1 25
$440.3M
$302.3M
Q4 24
$455.8M
$296.3M
Q3 24
$441.1M
$281.8M
Q2 24
$423.9M
$274.0M
Total Assets
CSTL
CSTL
NEWT
NEWT
Q1 26
$547.8M
Q4 25
$578.6M
$2.7B
Q3 25
$562.8M
$2.4B
Q2 25
$544.7M
$2.1B
Q1 25
$501.7M
$2.1B
Q4 24
$531.2M
$2.1B
Q3 24
$514.6M
$1.7B
Q2 24
$487.3M
$1.6B
Debt / Equity
CSTL
CSTL
NEWT
NEWT
Q1 26
0.02×
Q4 25
0.02×
2.06×
Q3 25
0.02×
1.94×
Q2 25
0.02×
2.11×
Q1 25
0.02×
2.56×
Q4 24
0.02×
2.39×
Q3 24
0.02×
2.33×
Q2 24
0.02×
2.38×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CSTL
CSTL
NEWT
NEWT
Operating Cash FlowLast quarter
$-22.1M
$-579.2M
Free Cash FlowOCF − Capex
$-579.3M
FCF MarginFCF / Revenue
-790.0%
Capex IntensityCapex / Revenue
0.1%
Cash ConversionOCF / Net Profit
-29.64×
TTM Free Cash FlowTrailing 4 quarters
$-1.0B

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CSTL
CSTL
NEWT
NEWT
Q1 26
$-22.1M
Q4 25
$26.9M
$-579.2M
Q3 25
$22.6M
$-167.3M
Q2 25
$20.8M
$-199.8M
Q1 25
$-6.0M
$-60.7M
Q4 24
$24.4M
$-153.0M
Q3 24
$23.3M
$-25.7M
Q2 24
$24.0M
$2.9M
Free Cash Flow
CSTL
CSTL
NEWT
NEWT
Q1 26
Q4 25
$19.7M
$-579.3M
Q3 25
$7.8M
$-167.3M
Q2 25
$11.6M
$-199.9M
Q1 25
$-10.8M
$-60.7M
Q4 24
$16.8M
$-153.5M
Q3 24
$17.0M
$-25.9M
Q2 24
$18.8M
$2.9M
FCF Margin
CSTL
CSTL
NEWT
NEWT
Q1 26
Q4 25
22.7%
-790.0%
Q3 25
9.4%
-223.3%
Q2 25
13.4%
-284.7%
Q1 25
-12.2%
-91.6%
Q4 24
19.5%
-203.6%
Q3 24
19.8%
-41.2%
Q2 24
21.6%
4.7%
Capex Intensity
CSTL
CSTL
NEWT
NEWT
Q1 26
Q4 25
8.3%
0.1%
Q3 25
17.9%
0.0%
Q2 25
10.7%
0.1%
Q1 25
5.4%
0.1%
Q4 24
8.8%
0.6%
Q3 24
7.4%
0.4%
Q2 24
6.0%
0.1%
Cash Conversion
CSTL
CSTL
NEWT
NEWT
Q1 26
Q4 25
-29.64×
Q3 25
-9.35×
Q2 25
4.60×
-14.58×
Q1 25
-6.48×
Q4 24
-8.35×
Q3 24
10.29×
-2.15×
Q2 24
2.69×
0.27×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons